Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum acyl-CoA synthetase 11 (PfACS11) is an enzyme of the acyl-CoA synthetase family involved in lipid metabolism in the malaria parasite. While not essential for growth in asexual blood stages in vitro, PfACS11 appears to play a significant role in mediating resistance to structurally diverse antimalarial compounds. Mutations in the PfACS11 gene are found in parasites that have acquired low-level resistance to specific antimalarial drugs, likely by decreasing protein stability or altering function. Therefore, while PfACS11 is not a primary drug target, it acts as an important mediator of drug resistance and is relevant in the context of surveillance for emerging antimalarial resistance.
For interacting drugs: PfACS11 is not the direct target; mutations in its gene enable resistance, possibly by altering protein stability or function. It acts as a resistance mediator rather than a direct point of compound inhibition.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum acyl-CoA synthetase 11 (PfACS11).